GlobeNewswire

London Court of Appeal Validates IPCom's Mobile Telecoms Patent Critical to the UMTS Standard

Dela

IPCom GmBH & Co. KG / London Court of Appeal Validates IPCom's Mobile Telecoms Patent Critical to the UMTS Standard . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Mobile Telecoms Patent is essential to UMTS networks

MUNICH, Germany, Jan. 09, 2018 (GLOBE NEWSWIRE) -- IPCom, a leading patent licensing entity with a global portfolio of mobile telecommunications patents, today announced that, earlier in 2017, the London Court of Appeal confirmed both the validity and infringement of IPCom's mobile telecoms European Patent (EP 1 841 268) (the "'100A") in its decision against the leading global handset vendor, HTC. The confirmation by the Court of Appeal of the validity of this critical patent and of HTC's infringement demonstrates the value and quality of this technology to mobile telecommunications companies.  In the event that the parties are unable to reach a settlement on the terms of a fair, reasonable and non-discriminatory ("FRAND") license, the parties will move next to the damages inquiry phase of the action.  In addition to the 100A action in the United Kingdom, as part of its ongoing effort to protect its intellectual property rights, IPCom recently filed a lawsuit against HTC in Germany for infringement of two additional IPCom patents. 

"We're pleased the Court found, after significant investigation and appeals, that the 100A is valid and essential to the UMTS standard," said Bernhard Frohwitter, managing director and co-founder of IPCom. "At long last, this paves the way for the industry as a whole to move forward with clear direction established by the court system. IPCom, with a portfolio of over 1,150 relevant or essential patents, stands ready to engage diligently with all manufacturers and service providers in the mobile industry."

Achieving this confirmation of validity and infringement was long and hard-fought but the decision by the Court of Appeal establishes that the 100A is standard-essential and mandatory to the UMTS standard. This particular patent is related to controlling how UMTS mobile telephones gain initial access to the network. As a result, any entity developing networks, handsets, or equipment for today's mobile networks should be engaging with IPCom regarding this critical element, as well as the hundreds of other relevant mobile technology patents within the firm's portfolio.

IPCom continues to engage with any industry participants who wish to take licenses on FRAND conditions as set forth by the European Commission and relayed to the European Telecommunications Standards Institute (ETSI). IPCom has a policy of offering all market participants implementing standards-compliant products and services FRAND licences and has been diligently doing so for many years. The confirmation of the 100A's validity and infringement by implementation of the UMTS standard reinforces the fact that UMTS implementors, if not already licensed, should be taking steps to negotiate with IPCom concerning its essential patent portfolio.

Companies manufacturing or selling mobile devices or offering services compliant with 2G (GMS), 2.5G (GPRS), 3G (UMTS) and 4G (LTE) should, therefore, contact IPCom to request a FRAND license agreement.  To request a license, please send your company name and contact information to ross@ipcom-munich.com

About IPCom
IPCom is a Patent Licensing Entity founded in 2007 to establish a link between patent developers and patent users. Its core business is the global licensing of patents from its own portfolio to manufacturers in the industry. Bosch originally developed IPCom's patents. The current patent portfolio encompasses approximately 1150 patents in the field of mobile communications, registered in Europe, the US and Asia. Among these are a number of patents that are declared standard-essential for the key mobile communications standards of 2G (GMS), 2.5G (GPRS), 3G (UMTS) and 4G (LTE).

For more information: 
Jay Nichols
Nichols Communications
jay@nicholscomm.com
Tel: +1 408-772-1551 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IPCom GmBH & Co. KG via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum